CAS number  Y
ChemSpider  N
Jmol-3D images Image 1
Molecular formula C23H22ClNO2
Molar mass 379.879 g·mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)

Licofelone is a dual COX/LOX inhibitor[1][2] being considered as a treatment for osteoarthritis[3] and which is under development by Merckle GmbH with partners Alfa Wassermann and Lacer.

Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-LOX may reduce the gastrointestinal toxicity associated with other non-steroidal anti-inflammatory drugs, which only inhibit COX (cyclooxygenase). Licofelone is the first drug to inhibit both. It has passed the phase III trials.[4]


  1. ^ Fischer L, Hornig M, Pergola C et al. (October 2007). "The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products". British Journal of Pharmacology 152 (4): 471–80. PMC 2050828. PMID 17704828. doi:10.1038/sj.bjp.0707416. 
  2. ^ Vidal C, Gómez-Hernández A, Sánchez-Galán E et al. (January 2007). "Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis". The Journal of Pharmacology and Experimental Therapeutics 320 (1): 108–16. PMID 17015640. doi:10.1124/jpet.106.110361. 
  3. ^ Alvaro-Gracia JM (February 2004). "Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis". Rheumatology (Oxford, England). 43 Suppl 1 (90001): i21–5. PMID 14752172. doi:10.1093/rheumatology/keh105. 
  4. ^